Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Core Viewpoint - Valneva SE, a specialty vaccine company, is actively engaging with investors through upcoming conferences in the U.S. and Europe, highlighting its vaccine pipeline and revenue expectations for 2025 [1][2]. Company Overview - Valneva SE develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, focusing on unmet medical needs and employing a specialized approach across various vaccine modalities [3]. - The company has a strong track record of advancing multiple vaccines from early R&D to approvals, currently marketing three proprietary travel vaccines, including the world's first chikungunya vaccine [4]. Financial Expectations - Valneva's marketed vaccines are projected to generate revenue between €170 million and €180 million in 2025 [2][5]. - The revenue from the commercial business supports the advancement of the vaccine pipeline, which includes the only Lyme disease vaccine candidate in advanced clinical development, partnered with Pfizer, and other candidates targeting global public health threats [5]. Upcoming Events - Valneva's CEO and CFO will present at the TD Cowen 45th Annual Health Care Conference in Boston from March 3-5, 2025, and will also meet with institutional investors at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 2-3, 2025 [1][2]. - The TD Cowen presentation will be available via live webcast [2].